Teva halts phase 2 trial of emrusolmin for multiple system atrophy after futility analysis

Teva Pharmaceuticals announced it is stopping a phase 2 study of its experimental small‑molecule drug emrusolmin, which was being tested in patients with the rare neurodegenerative condition multiple system atrophy (MSA).

The trial, which began in 2024 and enrolled about 350 participants, was overseen by an independent data monitoring committee. The committee recommended termination because the interim data indicated a low chance of achieving the primary efficacy endpoint.

No safety issues were reported, and Teva said it will review the full dataset before deciding on any further development of emrusolmin. The company remains committed to learning from the results.

Emrusolmin is being co‑developed with German biotech Modag. Teva expressed disappointment but thanked patients, families, investigators and study teams for their contributions.